Last edition
News about
GCCL and OPIS Forge Strategic Alliance to Expand Global Clinical Trial Services
GCCL, a South Korea-based leader in clinical trial sample analysis, and OPIS, a global full-service contract research organization (CRO), have entered into a Memorandum of Understanding (MoU) to deepen collaboration and enhance their footprint in the global clinical trial market.
Viz.ai Launches Real-Time Clinical Intelligence Service for Salesforce Agentforce Life Sciences
The new service integrates Viz.ai’s real-time clinical data from nearly 2,000 hospitals to power intelligent, closed-loop agentic workflows for life sciences organisations.
Russian Scientists Develop Chemical Method to Boost Anti-Cancer Drug Potency
Researchers in Russia have developed a novel chemical method that could significantly enhance the effectiveness of anti-cancer medicines, offering new momentum to oncology drug development.
US FDA Delays Two Drug Reviews Under New Priority Voucher Program
The U.S. Food and Drug Administration (FDA) has delayed the review of two medicines selected under its recently launched Commissioner’s National Priority Voucher Program, after regulators raised concerns related to safety and clinical effectiveness.
AbbVie Aligns Drug Development and Manufacturing Plans for Obesity Portfolio
AbbVie is moving to establish a strong presence in the obesity treatment market, with a strategy that emphasizes manufacturing scalability, supply readiness, and long-term production efficiency alongside clinical development.
Novo Nordisk Foundation Awards DKK 5.5 Billion to Boost Innovation in Denmark and Europe
The Novo Nordisk Foundation has awarded DKK 5.5 billion to support innovation in Denmark and Europe, enabling BioInnovation Institute (BII) to expand into new strategic areas and geographies. The funding aims to back a larger number of entrepreneurs and start-ups, strengthening the region’s life sciences and innovation ecosystem.
First Patient Dosed in New Beat AML Sub-Study Testing Triplet Therapy
Blood Cancer United launches a new Beat AML sub-study evaluating ficlatuzumab with venetoclax and azacitidine for newly diagnosed older adults with acute myeloid leukemia.
Biocon Raises INR 4,150 Crore via QIP
Biocon has successfully raised INR 4,150 crore through a Qualified Institutions Placement (QIP), with the proceeds set to be primarily used to fund the cash consideration payable to Mylan Inc. (Viatris) for the buyout of its stake in Biocon Biologics, including the repayment of related acquisition debt.
Boehringer Ingelheim Begins Phase IIa Trial of BI 765423 in IPF
Boehringer Ingelheim has initiated a Phase IIa clinical trial of BI 765423, a novel IL-11–targeting monoclonal antibody, in patients with Idiopathic Pulmonary Fibrosis (IPF), advancing its efforts to develop new treatment options for progressive fibrotic lung diseases.
Illumina Launches Billion Cell Atlas to Power AI-Driven Drug Discovery
Illumina, Inc. has launched the Illumina Billion Cell Atlas, the world’s largest genome-wide genetic perturbation dataset, designed to accelerate AI-enabled drug discovery across the pharmaceutical industry.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy